Wharton Alumni Angels: Pitch Event Featuring Women-Led Start-Ups

In honor of March being designated as National Women's History Month, Wharton Alumni Angels is excited to announce this upcoming pitch event featuring Women-Led Startup Companies listed below on 26-March from 4pm - 6:30pm PT // 7pm - 9:30pm ET. (Joining Information ➡️)

⭐ Minimum startup criteria to be considered for this event:

• Registered in the United States of America
• Currently raising capital at Series A or earlier round
• Lead investor in place (highly preferred)
• Has traction with customers [applicable to NON-life sciences and NON-therapeutics companies]
• Has achieved meaningful milestone(s) [applicable to life sciences and therapeutics companies]

⭐ This event is open to non-Wharton Alumni Angel Members - - Feel free to share this event information with interested parties! 

⭐ Each presenting company will be allotted 20 minutes for pitch presentation and Member Q&A.  The remaining time will be dedicated to a Discussion during which attending potential investors discuss each presentation.

     Innovotex and Tilden will be allotted 10 minutes for an update since their pitch presentation to WAA on 20-Nov-2024 and 26-Feb-2024 respectively.

⭐ Invited companies are screened by WAA's Screening Committee and selected based on a variety of criteria. 

PROPOSED AGENDA:

 Major Medical Devices

 is developing next-gen stent-grafts for aortic aneurysms that expand patient eligibility and streamline care.

PROBLEM: Abdominal Aortic Aneurysm is a life-threatening vascular condition afflicting 35M people worldwide. In 40% of cases, patients do not have an on-label minimally invasive treatment option due to devices that are ill-equipped for smaller, angulated, or diseased Access Anatomy. Women with AAA are disproportionately impacted by this lack of a solution.

SOLUTION: Our device is the first ever ultra-low profile endovascular stent graft for abdominal aortic and iliac aneurysms designed for single-site upper extremity access. This allows surgeons to take an entirely new treatment approach that bypasses challenging access anatomy entirely, bringing >35k patients on-label, and streamlining procedures for >180k.

LinkedIn 

Major Medical Pitch Deck

Submit DD Questions to Major Medical

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-major-medical

First in class macrocycle drug conjugates using a clinically validated tumor localizing vehicle and a novel payload.

PROBLEM: WT p53 cancers are aggressive tumors that often fail standard of care therapies. Platinum-based drugs are widely used, however 80-90% patients diagnosed with advanced disease will develop platinum resistance. Clinical utility is limited by multiple resistance factors that prevent wt p53 activation by traditional cisplatin/carboplatin treatment.

SOLUTION: InnovoTEX is developing an innovative drug discovery platform to identify and design targeted therapies that are well-tolerated, localize to solid tumors, and overcome platinum resistance targeting a unique mechanism known as ribosomal biosynthesis stress that induces wt-p53 activation and circumvents platinum resistance caused by DNA damage.

Website: http://www.innovotexinc.com/

Innovotex_Non Con CorporateOverview_Partnering Deck

Submit DD Questions to Innovotex

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-innovotex

Tilden crafts ready-to-pour non-alcoholic cocktails that delight the growing wave of non-drinkers and flexi-drinkers.

PROBLEM: 43% of Americans don't drink alcohol and another 40% are actively cutting back on alcohol consumption. That's a lot of parched people at restaurants and parties. As more and more consumers turn away from alcohol, existing options don't meet their needs: too much sugar, no sophistication in palate or craft, and childish branding and packaging.

SOLUTION: Tilden makes premium nonalcoholic cocktails that stir the senses. They are ready-to-pour and multi-award-winning. We live up to the cocktail occasion through our intentional craft and elevated packaging. We address key customer needs: clean ingredients, no added sugar, complex flavors, and a true cocktail finish to deliver the sip and swirl effect.

Website: http://www.drinktilden.com/

WAA-Tilden_Pitch Presentaiton_26-Feb-2025

Submit DD Questions to Tilden

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-tilden

We develop medical devices that simplify ear, nose, and throat procedures using our proprietary gel technology

PROBLEM: Middle ear infection is the most common childhood disease in the world. Over 1M US patients receive ear tubes annually, and there are about 5.3M patients with a chronic eardrum perforation from the ear tube or other trauma. Untreated perforations can result in recurring infection, hearing loss, and significantly decreased quality-of-life.

SOLUTION: Perf-Fix Otologic Gel Patch is a gel patch that transforms surgical eardrum repair into a 10-min clinic visit. Perf-Fix starts as a jelly that is applied to the eardrum through the ear canal, then cured with light to form a stiff gel that fills the perforation. The gel acts as a scaffold that allows cells to migrate and replace it with new tissue.

Website: http://www.tympanogen.com/

Tympanogen Pitch Deck_Tympanogen deck 03-24-2025 WAA

Deal Terms:

• Raise: $5 M Series A
• Raised to-date: $1.8 M
• Pre-money: $18 M
• Lead investor: Keiretsu Mid-Atlantic
• Terms: 1X Participating preferred equity, 20% warrant coverage
• No maximum allocation

Submit DD Questions to Tympanogen

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-tympanogen

The first fundamental new technology for surgical bleeding control since 1945, will upend $1.9B neurosurgery market.

PROBLEM: Bleeding control in neurosurgery is challenging due to sensitivity of tissues, anatomy & potential devastating impact of even small bleeds. Performance of current devices is marginal in neuro & leads to complication & reoperations, longer stays & re-admissions, all producing hundreds of millions of unreimbursed but avoidable costs for hospitals.

SOLUTION: Hand-held instrument delivers spray of natural polysaccharide solutions that form a 3-D device in place within 2 seconds. 1 application stops bleeding quickly (20 seconds), produces a stable clot via patented mechanisms of action, gently shrinks (no swelling). Reduces OR costs, complications & re-operations. Easier to use. Transparent, see thru.

Website: https://endomedix.com/

Endomedix Short Deck- 03.19.2025

Deal Terms:

• Seed round
• Structured priced round – preferred stock @ $1.00/ share + 10% warrant coverage
• Pre-money valuation is $7M. 
• $4.1M has already been invested, so $535K is available for investment
• All investors qualify for a 20% NJ Angel Investor Tax Credit (rebate)

Submit DD Questions to Endomedix

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-endomedix

LENTERNAL THERAPEUTICS, INC.

Lenternal delivers on the promise of durable cures for devastating diseases with one-time in vivo genetic medicines.

PROBLEM: Primary Immunodeficiencies (a group of genetic disorders) affect 1 in 1,200 people in the US. The few treatment options available are complex ex vivo gene therapies, which cost over $1 million and require hospitalization and invasive procedures. These ex vivo gene therapies use a lentiviral vector type which is unable to transduce cells in vivo.

SOLUTION: Our approach uses a novel lentiviral vector in vivo to target and transduce blood stem cells for durable genetic corrections. Our approach offers the proven curative benefits of ex vivo therapies at a lower cost with a simpler, less invasive patient experience. Our approach can bring curative potential for a wide group of genetic disorders.

Lenternal Tx Full CD90 Teaser Summer 2024 vAlumni Angels

Submit DD Questions to  LenternalTx

Dealum (WAA Members Only)

Slack (WAA Members Only): #1-lenternal-tx

----------

Wharton Alumni Angels is not a venture fund, an investment bank, a broker/dealer, investment clearing‐house, or an investment advisor. Wharton Alumni Angels is not registered with the U.S. Securities Exchange Commission or any other state’s or nation’s securities commission. For tax, compliance, reporting, legal or other requirements, it is highly recommended that members seek appropriate professional help. No representation or warranty is made as to the accuracy or completeness of the information provided by Wharton Alumni Angels or companies presenting investment opportunities. Wharton Alumni Angels presumes that any offering conducted by companies is a private placement and does not involve a public solicitation of investment.